A review of the receptor-binding and pharmacokinetic properties of dopamine agonists

Kvernmo, Trond; Härtter, Sebastian; Bürger, Erich

doi:10.1016/j.clinthera.2006.08.004

Cited by 249 publications

(212 citation statements)

References 57 publications

Supporting

Mentioning

195

Contrasting

Unclassified

Order By: Relevance

“…Although the primary binding site for pramipexole is the D3 receptor, its affinity to the D2 receptor remains high (Kvernmo et al, 2006). D2 receptors are localized to several brain regions that are critical to higher-order cognitive control (van Holstein et al, 2011), and D2 agonists such as bromocriptine have demonstrated pro-cognitive effects in healthy individuals (Kimberg et al, 1997;Luciana et al, 1998), particularly in cognitive domains linked to PFC functions.…”

Section: Discussionmentioning

confidence: 99%

Dopaminergic Influences on Emotional Decision Making in Euthymic Bipolar Patients

Burdick

Braga

Gopin

et al. 2013

Neuropsychopharmacol

View full text Add to dashboard Cite

We recently reported that the D2/D3 agonist pramipexole may have pro-cognitive effects in euthymic patients with bipolar disorder (BPD); however, the emergence of impulse-control disorders has been documented in Parkinson's disease (PD) after pramipexole treatment. Performance on reward-based tasks is altered in healthy subjects after a single dose of pramipexole, but its potential to induce abnormalities in BPD patients is unknown. We assessed reward-dependent decision making in euthymic BPD patients pre-and post 8 weeks of treatment with pramipexole or placebo by using the Iowa Gambling Task (IGT). The IGT requires subjects to choose among four card decks (two risky and two conservative) and is designed to promote learning to make advantageous (conservative) choices over time. Thirty-four BPD patients completed both assessments (18 placebo and 16 pramipexole). Baseline performance did not differ by treatment group (F ¼ 0.63; p ¼ 0.64); however, at week 8, BPD patients on pramipexole demonstrated a significantly greater tendency to make increasingly high-risk, high-reward choices across the five blocks, whereas the placebo group's pattern was similar to that reported in healthy individuals (treatment Â time Â block interaction, po0.05). Analyses of choice strategy using the expectancy valence model revealed that after 8 weeks on pramipexole, BPD patients attended more readily to feedback related to gains than to losses, which could explain the impaired learning. There were no significant changes in mood symptoms over the 8 weeks, and no increased propensity toward manic-like behaviors were reported. Our results suggest that the enhancement of dopaminergic activity influences risk-associated decision-making performance in euthymic BPD. The clinical implications remain unknown.

show abstract

Section: Discussionmentioning

confidence: 99%

Dopaminergic Influences on Emotional Decision Making in Euthymic Bipolar Patients

Burdick

Braga

Gopin

et al. 2013

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…Being a direct DA receptor agonist with predominant D2 activity, as well as a low-affinity ligand at serotonergic and adrenergic receptors (Kvernmo et al, 2006;Perachon et al, 1999), bromocriptine differs significantly from L-DOPA in its mechanisms of action. We therefore addressed the role of D1-like vs D2-like dopamine receptors in the angiogenic response to L-DOPA by using selective agonists and/or antagonists for these receptor classes.…”

Section: Discussionmentioning

confidence: 99%

“…This allowed us to ask the question, whether an increased motor activity per se may bring about microvascular remodeling in the basal ganglia, in analogy to the exercise-induced angiogenesis reported in other brain regions (Ekstrand et al, 2008a;Kleim et al, 2002;Swain et al, 2003). As bromocriptine exerts its motor stimulant ('anti-akinetic') effects predominantly by acting on the D2 receptor (Kvernmo et al, 2006;Perachon et al, 1999), it yields a different profile of DA receptor activation compared with L-DOPA. We thus addressed the specific role of D1-vs D2-like DA receptors in mediating angiogenic responses to treatment.…”

Section: Introductionmentioning

confidence: 99%

Differential Involvement of D1 and D2 Dopamine Receptors in L-DOPA-Induced Angiogenic Activity in a Rat Model of Parkinson's Disease

Lindgren

Ohlin

Cenci

2009

Neuropsychopharmacol

View full text Add to dashboard Cite

Angiogenesis occurs in the brains of Parkinson's disease patients, but the effects of dopamine replacement therapy on this process have not been examined. Using rats with 6-hydroxydopamine lesions, we have compared angiogenic responses induced in the basal ganglia by chronic treatment with either L-DOPA, or bromocriptine, or a selective D1 receptor agonist (SKF38393). Moreover, we have asked whether L-DOPA-induced angiogenesis can be blocked by co-treatment with either a D1-or a D2 receptor antagonist (SCH23390 and eticlopride, respectively), or by an inhibitor of extracellular signal-regulated kinases 1 and 2 (ERK1/2) (SL327). L-DOPA, but not bromocriptine, induced dyskinesia, which was associated with endothelial proliferation, upregulation of immature endothelial markers (nestin) and downregulation of endothelial barrier antigen in the striatum and its output structures. At a dose inducing dyskinesia (1.5 mg/kg/day), SKF38393 elicited angiogenic changes similar to L-DOPA. Antagonism of D1-but not D2 class receptors completely suppressed both the development of dyskinesia and the upregulation of angiogenesis markers. In fact, L-DOPA-induced endothelial proliferation was markedly exacerbated by low-dose D2 antagonism (0.01 mg/kg eticlopride). Inhibition of ERK1/2 by SL327 attenuated L-DOPA-induced dyskinesia and completely inhibited all markers of angiogenesis. These results highlight the specific link between treatment-induced dyskinesias and microvascular remodeling in the dopamine-denervated brain. L-DOPA-induced angiogenesis requires stimulation of D1 receptors and activation of ERK1/2, whereas the stimulation of D2 receptors seems to oppose this response.

show abstract

“…DAs with preferential affinity for the D3 receptor have strong association with ICB (Moore, Glenmullen, & Mattison, 2014). Pergolide has D3 receptor affinity (Kvernmo, Hartter, & Burger, 2006), and its use has been reported to be risk factors for the development of ICB (Weintraub et al., 2006). Consequently, pergolide might be associated with ICB persistence followed by ICB development.…”

Section: Discussionmentioning

confidence: 99%

The factors associated with impulse control behaviors in Parkinson's disease: A 2‐year longitudinal retrospective cohort study

et al. 2018

View full text Add to dashboard Cite

IntroductionImpulse control behaviors (ICBs) are impulsive–compulsive behaviors often associated with dopamine replacement therapy in Parkinson's disease (PD). Although remission can occur in ICB, only four reports on the ratio of remission and the persistence of ICB have been published, and the associated factors with ICB remission or persistence have been little known. Therefore, we conducted a longitudinal assessment of the remission, persistence, and development of ICB and those associated factors in patients with PD.MethodsWe retrospectively investigated a PD database at Aomori Prefectural Central Hospital, Japan. One hundred and forty‐eight patients with PD who could be followed up for 2 years were enrolled. ICB was assessed using the Questionnaire for Impulsive–Compulsive Disorders in Parkinson's disease. Motor severity (Hoehn and Yahr scale and United Parkinson's Disease Rating Scale), cognitive function (Mini–Mental State Examination), and other clinical variables (sex, age, onset age, disease duration, olfactory dysfunction, and dyskinesia) and medications used to treat PD were assessed. Univariate analyses were performed.ResultsSeven patients were excluded because of the exclusion criteria, and 141 patients were analyzed. Thirty patients (21.3%) had ICB at baseline, and these patients also had significantly higher use of pergolide. The ICB remission rate was 60%, the ICB persistence ratio was 40%, and the ICB development ratio was 12.6% over 2 years. Statistically, younger age and pergolide use were associated with ICB persistence. Being male, having dyskinesia, and rotigotine, entacapone, zonisamide, and istradefylline use were associated with ICB development.ConclusionThis study suggests that younger age and pergolide use may be the new associated factors with ICB persistence and that entacapone, zonisamide, and istradefylline use may be associated with the development of ICB. Drug profiles and medication practices in Japan may explain the association of these factors with ICB.

show abstract

A review of the receptor-binding and pharmacokinetic properties of dopamine agonists

Cited by 249 publications

References 57 publications

Dopaminergic Influences on Emotional Decision Making in Euthymic Bipolar Patients

Dopaminergic Influences on Emotional Decision Making in Euthymic Bipolar Patients

Differential Involvement of D1 and D2 Dopamine Receptors in L-DOPA-Induced Angiogenic Activity in a Rat Model of Parkinson's Disease

The factors associated with impulse control behaviors in Parkinson's disease: A 2‐year longitudinal retrospective cohort study

Contact Info

Product

Resources

About